Mounjaro (tirzepatide) and Ozempic (semaglutide) are two popular injectable medicines that help control blood sugar in type 2 diabetes. Both also cause meaningful weight loss, which leads many patients to compare them side by side. Cost often becomes the deciding factor because neither drug is cheap without insurance or assistance programs.
Prices vary widely depending on insurance coverage, pharmacy location, dose strength, and whether you use manufacturer savings cards. In many cases one medicine ends up significantly less expensive out of pocket than the other even when list prices look similar. Understanding the real-world cost differences helps patients and doctors choose the most affordable option that still meets treatment goals.
This article breaks down current pricing, insurance realities, savings programs, and practical ways to lower expenses. All figures reflect typical 2025–2026 U.S. retail and insured costs. Always check with your pharmacy and insurance plan for your exact amount.
List Prices Without Insurance
The manufacturer’s list price (also called wholesale acquisition cost or WAC) is the starting point before any discounts. Ozempic pens carry a list price of approximately $1,000 to $1,100 per month depending on the dose strength. A carton of four 2 mg pens usually falls in this range.
Mounjaro follows a similar pricing structure. The list price for most doses (5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg) sits around $1,060 to $1,100 per four-week supply. The starter doses (2.5 mg and 5 mg) sometimes appear slightly lower on certain pharmacy quotes.
Without any insurance or discount cards, both medicines cost roughly $1,000–$1,200 per month at retail pharmacies. Cash-paying patients rarely pay full list price because pharmacies and discount services offer reductions.
How Insurance Changes the Real Cost
Most commercial insurance plans place both drugs in higher tiers (Tier 3 or specialty tier). This means copays often range from $50 to $150 per month after deductible is met. Some plans require prior authorization and proof that other treatments failed first.
Medicare Part D coverage varies by plan. Ozempic is usually covered for type 2 diabetes with prior authorization, leading to copays of $0–$100 after the deductible. Mounjaro coverage has expanded but can still face stricter step therapy or quantity limits.
Medicaid coverage differs by state. Many states cover Ozempic readily for diabetes while Mounjaro may require more documentation. Weight-loss-only use is rarely covered under either program.
Manufacturer Savings Cards and Coupons
Novo Nordisk offers a savings card for Ozempic that reduces cost to as low as $25 per month for eligible commercially insured patients. The card covers up to 13 fills per year and has no income limit in most cases.
Eli Lilly provides a similar savings card for Mounjaro. Eligible patients pay $25 for a 1-month or 3-month supply depending on the program terms. The card works for commercially insured patients and has been widely accepted at major pharmacies.
Both cards exclude government insurance plans such as Medicare, Medicaid, and VA coverage. Patients must meet eligibility rules and activate the card through the manufacturer website or pharmacy.
Here is a clear 3-column comparison table of typical monthly costs:
| Coverage Type | Ozempic (typical) | Mounjaro (typical) |
|---|---|---|
| No insurance / cash pay | $950–$1,100 | $1,000–$1,100 |
| Commercial insurance + coupon | $25 (savings card) | $25 (savings card) |
| Medicare Part D (after deductible) | $0–$100 copay | $50–$150 copay |
| Medicaid (varies by state) | $0–$10 copay | $0–$25 copay |
| With prior authorization denial | Full price or alternative required | Full price or alternative required |
Pharmacy Discounts and Coupons Outside Manufacturer Programs
GoodRx, SingleCare, and other discount platforms often lower cash prices to $900–$1,000 per month for both drugs. These reductions help uninsured patients or those in the Medicare coverage gap.
Some independent pharmacies negotiate lower cash prices than big chains. Calling several pharmacies in your area can uncover savings of $50–$200 per month.
Manufacturer bridge programs sometimes provide free or low-cost medicine for a limited time when insurance denies coverage. These programs require proof of denial and financial information.
Dose Strength and Cost Differences
Ozempic pens come in 0.25/0.5 mg, 1 mg, and 2 mg strengths. The 2 mg pen is often the most cost-effective per milligram because it delivers four full doses. Patients on 1 mg or lower doses sometimes split pens or use fewer injections per month to stretch supply.
Mounjaro pens are dose-specific (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg). Higher doses cost the same per pen as lower ones, so titrating up does not increase monthly expense once you reach maintenance. This makes Mounjaro more predictable for budgeting at higher strengths.
Patients who stay on lower doses of either drug can sometimes reduce costs by using fewer pens over time or splitting doses under doctor guidance.
Prior Authorization and Step Therapy Impact
Most insurance plans require prior authorization for both medicines. Doctors must submit proof of type 2 diabetes diagnosis, recent A1C levels, and often failed trials of metformin or other generics.
Step therapy rules may force patients to try metformin, sulfonylureas, or DPP-4 inhibitors first. Ozempic sometimes faces fewer step requirements than Mounjaro in diabetes-focused plans.
Appeals succeed more often when the doctor includes detailed notes about side effects from previous drugs or specific reasons why alternatives are unsuitable.
Patient Assistance Programs for Low-Income Users
Novo Nordisk runs the Patient Assistance Program for Ozempic. Eligible uninsured or underinsured patients can receive the medicine free or at very low cost if household income falls below certain limits.
Eli Lilly offers a similar program for Mounjaro. Applications require proof of income, denial letters from insurance, and prescription details. Approval can take several weeks.
These programs help bridge gaps for patients who cannot afford the medicine even with discount cards. They do not cover government-insured individuals.
Ways to Lower Monthly Costs
Use manufacturer savings cards whenever eligible. Shop around at different pharmacies because cash prices vary by $100 or more in the same city. Ask your doctor about 90-day supplies to reduce copays and trips to the pharmacy.
Consider switching to a dose that allows pen sharing or fewer refills if your doctor agrees. Join diabetes support groups or online communities to learn about local pharmacy deals and coupon stacking.
If insurance denies coverage, ask for a letter of medical necessity. Some patients successfully appeal denials by providing additional lab results or specialist notes.
Practical tips to reduce out-of-pocket costs:
- Activate the manufacturer savings card before filling the first prescription.
- Compare prices on GoodRx, SingleCare, or pharmacy apps before going to the counter.
- Request 90-day supplies when insurance allows to lower copays.
- Ask your doctor about therapeutic alternatives if coverage is denied.
- Apply for patient assistance programs early if you meet income guidelines.
Long-Term Cost Considerations
Both medicines are intended for chronic use, so monthly costs accumulate over years. Patients who achieve significant weight loss and improve health markers sometimes reduce or eliminate other diabetes drugs, offsetting the expense.
Switching between Ozempic and Mounjaro can be cost-neutral if insurance covers both equally. Some patients alternate based on which one has better coverage in a given year.
Annual insurance plan changes during open enrollment often affect pricing. Reviewing formulary status each fall helps avoid surprises.
Monitoring Value Beyond Price
Cost is only one part of the decision. Better A1C control, greater weight loss, fewer heart events, and improved quality of life add value that outweighs higher prices for many patients.
Track A1C, weight, blood pressure, and energy levels every few months. These improvements justify the expense when cheaper alternatives do not deliver similar results.
Discuss cost concerns openly with your doctor. They can help prioritize treatment goals and find the most affordable path that still achieves health targets.
Conclusion
Mounjaro and Ozempic have similar list prices around $1,000–$1,100 per month, but real costs drop dramatically with insurance, savings cards, or assistance programs. Manufacturer coupons often bring the price to $25 for eligible patients, making the two medicines comparable in out-of-pocket expense. Compare your specific coverage, pharmacy options, and assistance eligibility to find the most affordable choice that fits your treatment needs.
FAQ
Which one is cheaper, Mounjaro or Ozempic?
List prices are very similar, usually $1,000–$1,100 per month for both. With manufacturer savings cards both can cost $25 for eligible commercially insured patients. Insurance coverage and pharmacy pricing determine the real difference.
Can I use the Ozempic savings card for Mounjaro?
No, each medicine has its own manufacturer savings card. Ozempic cards come from Novo Nordisk and Mounjaro cards from Eli Lilly. They are not interchangeable.
Does insurance cover one more easily than the other?
Ozempic often has broader coverage for type 2 diabetes due to earlier approval and extensive heart outcome data. Mounjaro coverage has grown quickly but may face stricter prior authorization or step therapy in some plans.
How can I get either medicine for $25 per month?
Activate the manufacturer savings card online or through your pharmacy. The card reduces cost to $25 per 1-month or 3-month supply for eligible patients with commercial insurance. Government plans are usually excluded.
Are patient assistance programs available for both drugs?
Yes, both Novo Nordisk and Eli Lilly offer patient assistance programs for uninsured or underinsured patients who meet income guidelines. Applications require proof of income and prescription details and can take several weeks for approval.
What if my insurance denies coverage for both medicines?
Appeal the denial with a letter of medical necessity from your doctor. Explore discount cards, patient assistance programs, or lower-cost alternatives such as other GLP-1 drugs or metformin combinations. Your doctor can help identify the best next step.
Dr. Usman is a medical content reviewer with 12+ years of experience in healthcare research and patient education. He specializes in evidence-based health information, medications, and chronic health topics. His work is based on trusted medical sources and current clinical guidelines to ensure accuracy, transparency, and reliability. Content reviewed by Dr. Usman is for educational purposes and does not replace professional medical advice.